YOLFTbeta
Sol Gel Technologies Ltd

Sol Gel Technologies Ltd

SLGL · NASDAQ · Healthcare / Biotechnology

55.12USD-1.13 (-2.01%)

Price History

Full chart

Market Stats

Previous Close56.25
Open56.80
Day Range53.44 – 57.78
52-Week Range27.00 – 97.97
Volume34.62K
Market Cap227.38M
P/E (TTM)0.00
Forward P/E9.34
EPS-5.87
Dividend Yield0.00%
Beta1.13
50-Day Avg75.07
200-Day Avg71.27

About

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Moshe Arkin
  • Employees28
  • Headquarters7 Golda Meir Street, Ness Ziona, Israel, 7403650, USA
  • Websitehttps://www.sol-gel.com

Leadership

  • Mr. Eyal Ben-OrChief Financial Officer · b. 1984
  • Dr. Itzik YosefChief Operating Officer · b. 1976
  • Mr. Michael GlezinChief Business Officer · b. 1983
  • Mr. Moshe ArkinCEO & Executive Chairman · b. 1953

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000174.00K129.00K22.90M8.77M31.27M3.88M1.55M11.54M19.39M
Growth (%)-----25.86%+17655.04%-61.71%+256.54%-87.58%-59.98%+642.47%+68.04%
Cost of Revenue0300.00K359.00K300.00K28.15M40.58M27.91M20.38M12.68M342.00K233.00K109.00K
Gross Profit0-300.00K-359.00K-126.00K-28.02M-17.67M8.77M10.89M-8.80M1.55M11.54M19.39M
Gross Margin----72.41%-21718.60%-77.17%100.00%34.83%-226.60%100.00%100.00%100.00%
Operating Expense4.81M9.35M20.40M31.51M5.50M-43.62M39.00M7.93M7.45M30.86M23.55M26.93M
Operating Income-4.81M-9.65M-20.76M-31.63M-33.52M25.95M-30.23M2.96M-16.24M-29.30M-12.01M-7.54M
Operating Margin----18179.89%-25985.27%113.30%-344.69%9.48%-418.34%-1885.78%-104.13%-38.88%
EBITDA-4.58M-9.35M-20.40M-31.16M-32.76M-25.06M-29.29M3.84M-15.68M-28.96M-11.78M-7.43M
EBITDA Margin----17909.20%-25394.57%-109.43%-333.91%12.29%-403.86%-1863.77%-102.11%-38.32%
Net Income-4.85M-9.66M-20.77M-31.57M-32.20M-24.61M-27.40M3.22M-14.92M-27.24M-10.58M-6.13M
Net Income Margin----18142.53%-24963.57%-107.44%-312.40%10.30%-384.32%-1752.77%-91.70%-31.60%
R&D2.93M7.18M17.02M25.80M28.15M40.58M27.91M20.38M12.68M23.54M17.80M22.80M
R&D as % of Total Revenue---14830.46%21818.60%177.17%318.24%65.17%326.60%1514.86%154.30%117.62%
Interest Expense000001.37M0880.00K1.32M---
Interest Expense % of Total Revenue---0.00%0.00%6.00%0.00%2.81%34.02%---

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.39M8.24M10.98M15.31M69.68M61.30M59.16M69.19M46.63M45.29M35.85M29.92M
Total Liabilities4.66M19.76M42.32M68.01M5.77M8.84M8.31M13.60M4.42M6.64M7.00M7.11M
Total Equity-2.99M-11.52M-31.34M-52.70M63.91M52.47M50.85M55.59M42.21M38.64M28.85M22.81M
Cash594.00K5.89M7.00M5.02M5.33M9.41M7.12M20.09M12.45M7.51M19.49M11.03M
Total Debt3.33M17.34M37.34M65.34M-2.04M1.97M1.59M772.00K1.65M1.31M991.00K
Net Debt2.74M11.44M30.34M60.31M-5.33M-7.37M-5.15M-18.49M-11.68M-5.86M-18.18M-10.04M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.83M-8.04M-18.50M-24.09M-23.47M-22.50M-25.24M-7.69M-9.48M-17.73M-13.89M322.00K
Investing Cash Flow897.00K-210.00K-391.00K-5.94M-54.73M16.02M-2.69M19.87M1.70M-9.74M26.69M-8.58M
Financing Cash Flow3.33M13.57M20.00M28.00M78.82M10.61M26.46M837.00K15.00K21.81M06.00K
Capital Expenditure268.00K291.00K385.00K1.93M1.05M597.00K449.00K143.00K171.00K134.00K2.00K47.00K
Free Cash Flow-5.10M-8.34M-18.88M-26.01M-24.52M-23.10M-25.69M-7.83M-9.65M-17.86M-13.89M275.00K
FCF to OCF105.55%103.62%102.08%107.99%104.48%102.65%101.78%101.86%101.80%100.76%100.01%85.40%

Earnings

Report DateMay 4, 2017Aug 29, 2017Nov 29, 2017Mar 26, 2018May 15, 2018Aug 8, 2018Nov 13, 2018Mar 21, 2019May 22, 2019Aug 13, 2019Nov 13, 2019Mar 24, 2020May 14, 2020Aug 6, 2020Nov 12, 2020Mar 4, 2021May 13, 2021Aug 4, 2021Nov 12, 2021Mar 30, 2022May 13, 2022Aug 4, 2022Nov 10, 2022Mar 10, 2023May 12, 2023Aug 10, 2023Nov 9, 2023Mar 13, 2024May 20, 2024Aug 16, 2024Nov 15, 2024Mar 31, 2025May 19, 2025Aug 15, 2025Nov 20, 2025Mar 11, 2026May 28, 2026Aug 20, 2026Nov 19, 2026
EPS Estimate0.000.000.00-0.61-4.17-5.10-5.72-5.85-0.60-2.77-2.60-0.34-4.00-3.77-5.17-0.41-4.57-1.83-3.300.41-2.90-0.97-0.65-0.12-2.15-2.55-2.30-1.75-0.15-1.90-0.50-0.11-0.12-0.70-2.090.40-1.63-2.31-1.71
EPS Actual-0.34-0.71-7.40-0.87-3.90-3.60-4.00-6.40-0.30-2.60-3.70-0.33-3.30-3.10-3.70-0.28-1.80-3.500.500.61-2.40-0.10-1.50-0.25-4.10-2.20-2.10-1.70-0.230.70-0.10-0.01-0.214.17-2.13-1.06-1.31-1.13-
Surprise----42.62%6.47%29.41%30.07%-9.40%50.00%6.14%-42.31%2.94%17.50%17.77%28.43%31.71%60.61%-91.26%115.15%48.78%17.24%89.69%-130.77%-108.33%-90.70%13.73%8.70%2.86%-53.33%136.84%80.00%90.91%-74.92%695.71%-1.91%-365.00%19.63%51.08%-
Timing---Pre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap227.38M
Enterprise Value150.20M
Trailing P/E0.00
Forward P/E9.34
Price / Sales126.67
Price / Book4.10
EPS-5.87
Book Value14.69
Revenue (TTM)1.79M
Gross Profit (TTM)-14.03M
EBITDA-17.69M
Profit Margin0.00%
Operating Margin-704.23%
Return on Equity-40.85%
Return on Assets-23.87%
Shares Outstanding3.27M
Shares Float489.00K
Beta1.13
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 152.50
  • Buy
    1

Ownership Breakdown

Institutions
43.05%
Insiders
59.61%
Retail / Other
0.00%

Top Institutional Holders

  • Opaleye Management Inc
    500.00K15.27%
  • Great Point Partners LLC
    274.36K8.38%
  • Phoenix Financial Ltd
    146.15K4.46%
  • Trails Edge Capital Partners, LP
    139.44K4.26%
  • Affinity Asset Advisors, LLC
    84.90K2.59%
  • Squadron Capital Management LLC
    52.00K1.59%
  • Citadel Advisors Llc
    32.56K0.99%
  • Stonepine Capital Management Llc
    27.78K0.85%
  • Yelin Lapidot Holdings Management Ltd
    10.38K0.32%
  • XTX Topco Ltd
    8.01K0.24%
  • MENORA MIVTACHIM HOLDINGS LIMITED
    7.61K0.23%
  • Jane Street Group LLC
    7.15K0.22%
  • Navellier & Associates Inc
    5.79K0.18%
  • Morgan Stanley - Brokerage Accounts
    5.17K0.16%
  • LPL Financial Corp
    3.47K0.11%
  • Millennium Management LLC
    3.34K0.10%
  • HRT FINANCIAL LLC
    3.21K0.10%

Top Fund Holders

  • ARK Israel Innovative Technology ETF
    28.15K0.86%
  • Mandarine Global Microcap G EUR
    2.80K0.09%
  • Fidelity Nasdaq Composite Index
    2.06K0.06%

Stock Splits

  • May 5, 20251:10